Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model.

scientific article published on 25 December 2017

Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.AMJMED.2017.12.010
P698PubMed publication ID29284111

P2093author name stringDavid van Klaveren
David M Kent
Marvin A Konstam
Jenica N Upshaw
P2860cites workThe effect of digoxin on mortality and morbidity in patients with heart failureQ73080377
An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinaseQ74499672
Clinical benefits of low serum digoxin concentrations in heart failureQ77772125
Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart AssociationQ22241921
Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposalQ24288920
Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial dataQ26796271
Risk and treatment effect heterogeneity: re-analysis of individual participant data from 32 large clinical trialsQ31112168
Evaluating the yield of medical testsQ34277948
Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trialQ34647669
Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program.Q35158163
Estimating treatment effects for individual patients based on the results of randomised clinical trialsQ35252544
Digitalis for treatment of congestive heart failure in patients in sinus rhythm: a systematic review and meta-analysisQ35752516
Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trialQ37066497
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart AssociationQ37538031
Multistate Model to Predict Heart Failure Hospitalizations and All-Cause Mortality in Outpatients With Heart Failure With Reduced Ejection Fraction: Model Derivation and External ValidationQ38388968
Rehospitalizations among patients in the Medicare fee-for-service programQ39513280
Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithmQ40832107
Aggregating and disaggregating patients in clinical trials and their subgroup analysesQ42417534
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trialQ43239377
The mstate package for estimation and prediction in non- and semi-parametric multi-state and competing risks models.Q51714177
Heart failure in outpatients: a randomized trial of digoxin versus placeboQ70221207
Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE StudyQ70746802
Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failureQ71297666
Association of serum digoxin concentration and outcomes in patients with heart failureQ73004928
P407language of work or nameEnglishQ1860
P921main subjectheart failureQ181754
digoxinQ422222
hospitalizationQ3140971
P577publication date2017-12-25
P1433published inAmerican Journal of MedicineQ2842959
P1476titleDigoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model.

Reverse relations

Q89304755Pharmacologic Management of Cancer Therapeutics-Induced Cardiomyopathy in Adult Cancer Survivorscites workP2860

Search more.